Smoking Cessation Intervention for Reducing Cigarette Use
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how thinking about future positive events can help people reduce cigarette smoking. Participants will either focus on future events they anticipate or recall positive past events. The goal is to determine if envisioning exciting future events can motivate smokers to reduce cigarette consumption. This trial suits individuals who smoke at least 10 cigarettes daily, own a smartphone, and wish to quit smoking within the next month. As an unphased trial, it offers a unique opportunity to explore new strategies for quitting smoking.
Will I have to stop taking my current medications?
The trial requires that you are not currently using nicotine replacement therapy, bupropion, or varenicline. If you are using these, you would need to stop before participating.
What prior data suggests that this method is safe for reducing cigarette use?
Research shows that thinking about future events, known as episodic future thinking (EFT), can help people reduce smoking. Previous studies have demonstrated that EFT encourages individuals to focus on positive future events, which may influence their smoking habits.
EFT is safe because it involves no physical treatment. As a mental exercise, it lacks the side effects that medications might have. Studies on EFT have not reported any negative effects, suggesting it is a safe and well-tolerated method for helping people reconsider their smoking habits.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores a unique smoking cessation approach using Emotional Freedom Techniques (EFT) combined with the iCOquit Smokerlyzer carbon monoxide monitor. Unlike traditional methods like nicotine replacement therapy or medications such as varenicline, EFT is a psychological acupressure technique that aims to reduce cravings and stress associated with quitting smoking. By measuring carbon monoxide levels with the Smokerlyzer, participants receive real-time feedback on their progress, which could enhance motivation and success rates. This trial could uncover new ways to help smokers quit by addressing both physiological and psychological aspects of addiction.
What evidence suggests that this trial's treatments could be effective for reducing cigarette use?
Research shows that thinking about positive future events, known as episodic future thinking (EFT), can help smokers reduce cigarette consumption. In this trial, participants in Arm 1 will receive the active EFT stimulus. Studies have found that EFT reduces both the urge to smoke and the number of cigarettes smoked. One study found that combining EFT with cognitive behavioral therapy lowered nicotine use by about 69%. Another study demonstrated that EFT helped individuals become less focused on immediate rewards, with a moderate impact. These findings suggest that EFT can be a powerful tool for those aiming to reduce smoking.678910
Who Is on the Research Team?
Christine Sheffer
Principal Investigator
Roswell Park
Are You a Good Fit for This Trial?
This trial is for cigarette smokers who smoke at least 10 cigarettes daily, do not use other tobacco products regularly, have a smartphone with texting ability, and can vividly imagine visual images. People using nicotine replacements or certain medications, those who've used drugs of abuse recently, or live with someone in the study cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the active or control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Medical Device Usage and Evaluation
- Smoking Cessation Intervention
- Smoking Cessation Intervention (control)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor